ACQUISITIONS and MERGERS
1 min.Read

GTCR-Backed Resonetics Acquires Distal Solutions

GTCR, a leading private equity firm, announced today that Resonetics has completed an acquisition of Distal Solutions.

Distal Solutions (“Distal”), based in Westborough, Massachusetts, specializes in the design and development of catheter-based delivery systems for interventional medical devices and implants.

Distal’s founder David Rezac, a 15-year veteran of the contract design and development industry, will lead Resonetics’ design and development efforts as well as further expansion in the California market. Distal Solutions represents the sixth add-on acquisition since GTCR invested in Resonetics in February 2018.

The acquisition furthers the company’s strategy to build a market leader in precision micro-manufacturing and design of complex interventional medical devices and componentry. With the addition of Distal’s design and development capabilities, Resonetics aims to further accelerate product development cycles and help customers advance their innovative product concepts to market more quickly.

GTCR made its initial investment in Resonetics in partnership with medical device industry executive Robert “Chip” Hance. GTCR initially partnered with Mr. Hance to form Regatta Medical in April 2017 to pursue opportunities in the medical device sector, and the investment in Resonetics represented another example of how GTCR executes The Leaders StrategyTM. Since GTCR’s investment, Mr. Hance has partnered with the Resonetics team, including CEO Tom Burns, to significantly grow the company’s revenue and EBITDA through organic growth and strategic add-on acquisitions.

Chip Hance, Executive Chairman of Resonetics, commented, “Consistent with our initial investment thesis for Resonetics, the acquisition of Distal Solutions strategically enhances Resonetics’ capabilities, and further establishes the company’s position as a leading service provider to interventional medical device companies.”

Sean Cunningham, Managing Director at GTCR, added, “We have great respect for what David and the Distal team has built, and we look forward to our partnership with them. This represents Resonetics’ sixth acquisition since our initial investment, and we expect to continue to aggressively pursue tuck-in acquisitions as well as more transformative opportunities.”

Kirkland & Ellis LLP provided legal counsel and PricewaterhouseCoopers served as accounting advisor to GTCR.

SourceGTCR

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330